Navigation Links
Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
Date:9/7/2007
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Space sensors shed new light on air quality 2Health News:Space sensors shed new light on air quality 3Health News:China Medical Technologies to Announce Financial Results for the Second Quarter Ended September 30, 2007 on November 20, 2007 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:SAIC to Collaborate with UK Biometrics Institute 2Health News:SAIC to Collaborate with UK Biometrics Institute 3Health News:Spending more for lung cancer treatment did not substantially increase patients' lives 2Health News:Northwestern Memorial Hospital Completes Move Into Its New Prentice Women's Hospital 2Health News:Northwestern Memorial Hospital Completes Move Into Its New Prentice Women's Hospital 3
Breaking Medicine Technology:Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 2Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2LFAGW to Run Could I Have Lupus 3F Workshop on July 26 3B Mystics Game Follows 51830 1LFAGW to Run Could I Have Lupus 3F Workshop on July 26 3B Mystics Game Follows 51830 2LFAGW to Run Could I Have Lupus 3F Workshop on July 26 3B Mystics Game Follows 51830 3ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results 51826 1ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results 51826 2New Data Say Uninsured Account for Nearly One Fifth of Emergency Room Visits 51823 1New Data Say Uninsured Account for Nearly One Fifth of Emergency Room Visits 51823 2New Data Say Uninsured Account for Nearly One Fifth of Emergency Room Visits 51823 3